Oct 26 2004
The Boston Globe reports
on the third-quarter MoneyTree survey of national venture capital activity that the region had a steep drop in venture financing in the third quarter: down 57% from the second quarter, compared to a national decline of 26%.
Divining the reasons is difficult as the summer quarter is traditionally the slowest for v.c. activity in any region. The question is what is driving the region so much lower than the rest of the country? My sense is that IT investment opportunities – the traditional bedrock of the region – have all but dried up. If the early 90s were driven by networking startups founded by displaced minicomputer engineering talent tossed on the street by the extinction of the dinosaurs at DEC, Wang, Data General, et al – Stratacom, Chipcom, etc. – the early part of this decade hasn’t seen the talent spinoffs expected from the region’s early strengths in search services. Alta Vista and Lycos in particular did not cast off much of a halo effect, and the dot.com froth seemed particularly harsh up in Andover as CMGI flailed through its last stages as an investment holding company before being reborn under George McMillan out of the ashes of an incubator into a focus on supply chain management via SalesLink.
The VCs in the region have traditionally been the more sober members of the species, exemplified by firms such as Charles River Ventures which steered clear of the dot.coms and focused on companies such as Parametric. I sense that with a lot of overhang from uninvested funds, the region’s VCs are following two strategies: one, if you don’t know what to do, don’t do anything; and second, if you can’t spend what you have, don’t raise more.
The transition from an IT/software technology economy to the life sciences is the big regional story. Lifesciences startup salaries are the highest in the nation in New England, and where the talent goes, so goeth the dollars. Indeed, as the MoneyTree survey reports, the largest percentage of the third quarter funding activity went into the life sciences.